PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 1, 2022Journal of the National Comprehensive Cancer Network174 citationsOpen Access

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

View Full Paper
SHSteven M. HorwitzSAStephen M. AnsellWAWeiyun Z. Ai

Key Points

Key points are not available for this paper at this time.

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Horwitz et al. (2022) studied this question.

synapsesocial.com/papers/69d8f54c2c87b79b92d18606https://doi.org/10.6004/jnccn.2022.0015
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.2005 · 87 citations
  2. 2CD30 expression in peripheral T-cell lymphomas2013 · 163 citations
  3. 3Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment2016 · 22 citations
  4. 4The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study2019 · 149 citations
  5. 5Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial2020 · 93 citations